<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-3347</journal-id>
<journal-title><![CDATA[Colombian Journal of Anestesiology]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. anestesiol.]]></abbrev-journal-title>
<issn>0120-3347</issn>
<publisher>
<publisher-name><![CDATA[SCARE-Sociedad Colombiana de Anestesiología y Reanimación]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-33472020000200063</article-id>
<article-id pub-id-type="doi">10.1097/cj9.0000000000000147</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cost-benefit relationship of keeping dantrolene stocks from the point of view of healthcare institutions]]></article-title>
<article-title xml:lang="es"><![CDATA[Relación costo-efectividad del abastecimiento de dantroleno desde el punto de vista del prestador de servicios de salud]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincón-Valenzuela]]></surname>
<given-names><![CDATA[David A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Ardila]]></surname>
<given-names><![CDATA[Ciro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica Universitaria Colombia Operating Room Department ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia School of Medicine ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de La Sabana  ]]></institution>
<addr-line><![CDATA[ Chía]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>48</volume>
<numero>2</numero>
<fpage>63</fpage>
<lpage>70</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-33472020000200063&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-33472020000200063&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-33472020000200063&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Malignant hyperthermia (MH) is an acute syndrome triggered by certain anesthetic medications. Dantrolene is the only specific treatment for MH crises. Without treatment, lethality may be as high as 80%. In Colombia, it is not mandatory to keep dantrolene supplies in stock.  Objective: To establish the cost-benefit ratio, from the perspective of healthcare institutions, of keeping dantrolene supplies in stock in the operating theater.  Methods: Using a decision tree, a Monte Carlo simulation was run with 10,000 scenarios to determine the median annual cost of keeping full or partial stocks (36 or 12 vials x 20 mg, respectively) of dantrolene. For the option of not keeping supplies in stock, the cost threshold was calculated where the expected value of both alternatives of the decision tree is equalized. Indifference curves were constructed for complete and partial supplies.  Results: The median annual cost was estimated at 6.6 million Colombian pesos (COP) for full dantrolene supplies, and at COP 2.2 million for partial supplies. The median economic consequence threshold for 1 death due to the unavailability of dantrolene was estimated at COP 18.5 million for full supplies, and at COP 57.0 million for partial supplies.  Conclusion: If, as a result of the unavailability of dantrolene, the economic consequences of a death due to MH exceed the threshold of COP 57.0 or COP 18.5 million, the purchase of full or partial stocks, respectively, is justified.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La hipertermnia maligna (HM) es un síndrome agudo desencadenado por algunos medicamentos anestésicos. El dantroleno es el único tratamiento específico para las crisis de HM. Sin tratamiento puede tener una letalidad cercana al 80%. En Colombia, el abastecimiento de dantroleno no es obligatorio.  Objetivo: Establecer la relación costo-efectividad, desde el punto de vista de las instituciones prestadoras de servicios de salud, de mantener un abastecimiento de dantroleno en quirófanos.  Métodos: Mediante un árbol de decisiones se realizó una simulación Monte Carlo con 10 mil escenarios para determinar la mediana del costo anual de un abastecimiento completo o parcial (36 o 12 viales de 20 mg, respectivamente) de dantroleno. Para la alternativa de no tener abastecimiento, se calculó el umbral de costo, donde se iguala el valor esperado de ambas alternativas del árbol de decisiones. Se construyeron curvas de indiferencia para el abastecimiento completo y parcial.  Resultados: La mediana del costo anual del abastecimiento completo de dantroleno se estimó en $6.6 millones de pesos colombianos (COP), y el del abastecimiento parcial en $2.2 millones COP. La mediana del umbral de consecuencias económicas por una muerte sin disponibilidad de dantroleno se estimó en 18.5 millones COP para el abastecimiento completo, y en 57.0 millones COP para el abastecimiento parcial.  Conclusión: Si por no disponer de dantroleno las consecuencias económicas de una muerte por HM superan el umbral de $57.0 o $18.5 millones COP, se justifica la compra de un abastecimiento completo o parcial, respectivamente.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Anesthesia]]></kwd>
<kwd lng="en"><![CDATA[Malignant Hyperthermia]]></kwd>
<kwd lng="en"><![CDATA[Dantrolene]]></kwd>
<kwd lng="en"><![CDATA[Economics]]></kwd>
<kwd lng="en"><![CDATA[Hospital]]></kwd>
<kwd lng="en"><![CDATA[Economics]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical]]></kwd>
<kwd lng="en"><![CDATA[Decision Making]]></kwd>
<kwd lng="en"><![CDATA[Organizational]]></kwd>
<kwd lng="es"><![CDATA[Anestesia]]></kwd>
<kwd lng="es"><![CDATA[Hipertermia maligna]]></kwd>
<kwd lng="es"><![CDATA[Dantroleno]]></kwd>
<kwd lng="es"><![CDATA[Economía hospitalaria]]></kwd>
<kwd lng="es"><![CDATA[Farmacoeconomía]]></kwd>
<kwd lng="es"><![CDATA[Toma de decisiones en la organización]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pollock]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schiemann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia a review]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>93</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim D-C]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia]]></article-title>
<source><![CDATA[Korean J Anesthesiol]]></source>
<year>2012</year>
<volume>63</volume>
<page-range>391-401</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ording]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of malignant hyperthermia in Denmark]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>1985</year>
<volume>64</volume>
<page-range>700-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortiz Gómez]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anesthesia in malignant hyperthermia]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2008</year>
<volume>55</volume>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>2009</year>
<volume>109</volume>
<page-range>1162-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumitani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Uchida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yasunaga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of malignant hyperthermia and relationship with anesthetics in Japan data from the diagnosis procedure combination database]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2011</year>
<volume>114</volume>
<page-range>84-90</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Denborough]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug treatment of malignant hyperpyrexia]]></article-title>
<source><![CDATA[Anaesth Intensive Care]]></source>
<year>1977</year>
<volume>5</volume>
<page-range>207-13</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krause]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gerbershagen]]></surname>
<given-names><![CDATA[MU]]></given-names>
</name>
<name>
<surname><![CDATA[Fiege]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dantrolene-a review of its pharmacology, therapeutic use and new developments]]></article-title>
<source><![CDATA[Anaesthesia]]></source>
<year>2004</year>
<volume>59</volume>
<page-range>364-73</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Litman]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[VI]]></given-names>
</name>
<name>
<surname><![CDATA[Larach]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>2019</year>
<volume>128</volume>
<page-range>652-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Denborough]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lovell]]></surname>
<given-names><![CDATA[RRH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anaesthetic deaths in a family]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1960</year>
<volume>276</volume>
<page-range>45</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Britt]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Kalow]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia a statistical review]]></article-title>
<source><![CDATA[Can Anaesth SocJ]]></source>
<year>1970</year>
<volume>17</volume>
<page-range>293-315</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-benefit analysis of maintaining a fully stocked malignant hyperthermia cart versus an initial dantrolene treatment dose for maternity units]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2018</year>
<volume>129</volume>
<page-range>249-59</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baquero Molina]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo Londoño]]></surname>
<given-names><![CDATA[ÁM]]></given-names>
</name>
</person-group>
<source><![CDATA[Propuesta para el manejo de la hipertermia maligna en la red integrada de servicios de salud]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría Distrital de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neira]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertermia maligna en Latinoamérica]]></article-title>
<source><![CDATA[Colombian Journal of Anesthesiology]]></source>
<year>1993</year>
<volume>21</volume>
<page-range>385-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfenninger]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Heiderich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Klingler]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stocks of dantrolene in anesthesia and intensive care units in Germany]]></article-title>
<source><![CDATA[Anaesthesist]]></source>
<year>2017</year>
<volume>66</volume>
<page-range>773-81</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larach]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Klumpner]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Brandom]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Succinylcholine use and dantrolene availability for malignant hyperthermia treatment database analyses and systematic review]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2019</year>
<volume>130</volume>
<page-range>41-54</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raftery]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economics notes opportunity cost]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1999</year>
<volume>318</volume>
<page-range>1551-2</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health economic evaluation a primer for healthcare professionals]]></article-title>
<source><![CDATA[Prim Health Care Open Access]]></source>
<year>2016</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bojke]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Manca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Asaria]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to appropriately extrapolate costs and utilities in cost-effectiveness analysis]]></article-title>
<source><![CDATA[PharmacoEconomics]]></source>
<year>2017</year>
<volume>35</volume>
<page-range>767-76</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[In]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of malignant hyperthermia in patients undergoing general anesthesia protocol for a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2017</year>
<volume>96</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strazis]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia a review of published cases]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>1993</year>
<volume>77</volume>
<page-range>297-304</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aderibigbe]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2014</year>
<volume>120</volume>
<page-range>1333-8</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Larach]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia in Canada characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>2014</year>
<volume>118</volume>
<page-range>381-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The meaning of binomial distribution]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1960</year>
<volume>186</volume>
<page-range>1074</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wiberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[von Davier]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A note on the Poisson&#8217;s binomial distribution in item response theory]]></article-title>
<source><![CDATA[Appl Psychol Meas]]></source>
<year>2016</year>
<volume>40</volume>
<page-range>302-10</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glahn]]></surname>
<given-names><![CDATA[KPE]]></given-names>
</name>
<name>
<surname><![CDATA[Ellis]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
<name>
<surname><![CDATA[Halsall]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recognizing and managing a malignant hyperthermia attack guidelines from the European Malignant Hyperthermia Group]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2010</year>
<volume>105</volume>
<page-range>417-20</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kollmann-Camaiora]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alsina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical protocol for the management of malignant hyperthermia]]></article-title>
<source><![CDATA[Rev Esp Anestesiol Reanim]]></source>
<year>2017</year>
<volume>64</volume>
<page-range>32-40</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rincón-Valenzuela]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Sessler]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo Mejía]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverry Marín]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Menéndez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Hipertermia maligna. Tratado de anestesia pediátrica]]></source>
<year>2015</year>
<page-range>1034-71</page-range><publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[S.C.A.R.E]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Por fin dantroleno?]]></article-title>
<source><![CDATA[Colombian Journal of Anesthesiology]]></source>
<year>2004</year>
<volume>32</volume>
<page-range>87-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[WU]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant hyperthermia and dantrolene sodium]]></article-title>
<source><![CDATA[Korean J Anesthesiol]]></source>
<year>2019</year>
<volume>72</volume>
<page-range>78-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosero]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Adesanya]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Timaran]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2009</year>
<volume>110</volume>
<page-range>89-94</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records]]></article-title>
<source><![CDATA[Paediatr Anaesth]]></source>
<year>2011</year>
<volume>21</volume>
<page-range>958-63</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Husereau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Petrou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consolidated health economic evaluation reporting standards (CHEERS) statement]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2013</year>
<volume>16</volume>
<page-range>e1-5</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brannon]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[What is a life worth?Rochester,]]></source>
<year>2005</year>
<publisher-loc><![CDATA[NY ]]></publisher-loc>
<publisher-name><![CDATA[Social Science Research Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kniesner]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Viscusi]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Woock]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The value of a statistical life evidence from panel data]]></article-title>
<source><![CDATA[Rev Econ Stat]]></source>
<year>2012</year>
<volume>94</volume>
<page-range>74-87</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveros]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cirugía cardíaca en un paciente sospechoso de hipertermia maligna]]></article-title>
<source><![CDATA[Colombian Journal of Anesthesiology]]></source>
<year>1993</year>
<volume>21</volume>
<page-range>403-6</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neira]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertermia maligna en Bogotá]]></article-title>
<source><![CDATA[Colombian Journal of Anesthesiology]]></source>
<year>1993</year>
<volume>21</volume>
<page-range>385-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
